Abnormal protein tyrosine phosphorylation in fibroblasts from hyperapobetalipoproteinemia subjects. 1997

M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
Lipid Research Atherosclerosis Unit, Bernard Laboratory, Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-3654, USA.

The stimulatory effects of three normal human serum basic proteins (BP), BP I (Mr 14,000, pI 9.10), BP II (Mr 27, 500, pI 8.48), and BP III (Mr 55,000, pI 8.73) on cellular triglyceride and cholesterol formation require intact protein-tyrosine kinase phosphorylation (TKP). Here we examined whether there is an abnormality in TKP in cultured fibroblasts from 11 patients with hyperapobetalipoproteinemia (hyperapoB) that manifest two acylation-stimulatory defects, decreased stimulation of triglyceride synthesis by BP I but enhanced formation of cholesterol by BP II. Soluble and insoluble proteins in Triton X-100 extracts were isolated by immunoprecipitation with a monoclonal anti-phosphotyrosine antibody (MAPA) bound to agarose beads and by ultracentrifugation, respectively, from confluent fibroblasts after incubation for 24 h in supplemented serum-free and lipid-free medium (DMEM/F12). Western blots of insoluble proteins showed that group (Gp) II (Mr 36,000-55,000) and Gp III (Mr 14,000-35,000) from hyperapoB cells, grown in DMEM/F12 medium without BP, had significantly decreased reactivity to MAPA. No significant differences in reactivity to MAPA were detected between normal and hyperapoB cells for Gp I (Mr 97-120,000). BP II, but not BP I or BP III, reversed the decreased reactivity of Gp II and Gp III to MAPA in hyperapoB cells. Sodium vanadate, an inhibitor of phosphotyrosine phosphatases, did not reverse the deficiency in TKP or the 50% deficiency in the stimulation of mass triglyceride by BP I in hyperapoB cells. Tyrosine-phosphorylated Erk-2, a mitogen-activated protein kinase, identified as one of the proteins in Gp II, was significantly decreased in hyperapoB cells. These results provide further evidence for abnormal protein TKP in hyperapoB cells and suggest a possible link between atherosclerotic changes in hyperapoB patients and growth factors upstream from mitogen-activated protein kinase.

UI MeSH Term Description Entries
D006951 Hyperlipoproteinemias Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation. Hyperlipoproteinemia
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001055 Apolipoproteins B Major structural proteins of triacylglycerol-rich LIPOPROTEINS. There are two forms, apolipoprotein B-100 and apolipoprotein B-48, both derived from a single gene. ApoB-100 expressed in the liver is found in low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). ApoB-48 expressed in the intestine is found in CHYLOMICRONS. They are important in the biosynthesis, transport, and metabolism of triacylglycerol-rich lipoproteins. Plasma Apo-B levels are high in atherosclerotic patients but non-detectable in ABETALIPOPROTEINEMIA. Apo-B,Apo B,ApoB,Apoprotein (B),Apoproteins B
D017027 Protein Tyrosine Phosphatases An enzyme group that specifically dephosphorylates phosphotyrosyl residues in selected proteins. Together with PROTEIN-TYROSINE KINASE, it regulates tyrosine phosphorylation and dephosphorylation in cellular signal transduction and may play a role in cell growth control and carcinogenesis. Phosphotyrosine Phosphatase,Protein-Tyrosine-Phosphatase,Tyrosyl Phosphoprotein Phosphatase,PTPase,Phosphotyrosyl Protein Phosphatase,Protein-Tyrosine Phosphatase,Phosphatase, Phosphotyrosine,Phosphatase, Phosphotyrosyl Protein,Phosphatase, Protein-Tyrosine,Phosphatase, Tyrosyl Phosphoprotein,Phosphatases, Protein Tyrosine,Phosphoprotein Phosphatase, Tyrosyl,Protein Phosphatase, Phosphotyrosyl,Protein Tyrosine Phosphatase,Tyrosine Phosphatases, Protein
D017871 Calcium-Calmodulin-Dependent Protein Kinases A CALMODULIN-dependent enzyme that catalyzes the phosphorylation of proteins. This enzyme is also sometimes dependent on CALCIUM. A wide range of proteins can act as acceptor, including VIMENTIN; SYNAPSINS; GLYCOGEN SYNTHASE; MYOSIN LIGHT CHAINS; and the MICROTUBULE-ASSOCIATED PROTEINS. (From Enzyme Nomenclature, 1992, p277) Ca(2+)-Calmodulin-Dependent Protein Kinase,Calcium-Calmodulin-Dependent Protein Kinase,Calmodulin-Dependent Protein Kinase,Calmodulin-Dependent Protein Kinases,Multifunctional Calcium-Calmodulin-Dependent Protein Kinase,Restricted Calcium-Calmodulin-Dependent Protein Kinase,Calcium-Calmodulin-Dependent Protein Kinases, Multifunctional,Calcium-Calmodulin-Dependent Protein Kinases, Restricted,Calmodulin-Dependent Multiprotein Kinase,Calmodulin-Kinase,Cam-MPK,Multifunctional Calcium-Calmodulin-Dependent Protein Kinases,Restricted Calcium-Calmodulin-Dependent Protein Kinases,Calcium Calmodulin Dependent Protein Kinase,Calcium Calmodulin Dependent Protein Kinases, Multifunctional,Calcium Calmodulin Dependent Protein Kinases, Restricted,Calmodulin Dependent Multiprotein Kinase,Calmodulin Dependent Protein Kinase,Calmodulin Dependent Protein Kinases,Calmodulin Kinase,Cam MPK,Kinase, Calcium-Calmodulin-Dependent Protein,Kinase, Calmodulin-Dependent Protein,Multifunctional Calcium Calmodulin Dependent Protein Kinase,Multifunctional Calcium Calmodulin Dependent Protein Kinases,Multiprotein Kinase, Calmodulin-Dependent,Protein Kinase, Calcium-Calmodulin-Dependent,Protein Kinase, Calmodulin-Dependent,Protein Kinases, Calcium-Calmodulin-Dependent,Protein Kinases, Calmodulin-Dependent,Restricted Calcium Calmodulin Dependent Protein Kinase,Restricted Calcium Calmodulin Dependent Protein Kinases
D019950 Mitogen-Activated Protein Kinase 1 A proline-directed serine/threonine protein kinase which mediates signal transduction from the cell surface to the nucleus. Activation of the enzyme by phosphorylation leads to its translocation into the nucleus where it acts upon specific transcription factors. p40 MAPK and p41 MAPK are isoforms. Extracellular Signal-Regulated Kinase 2,MAP Kinase 2,Mitogen-Activated Protein Kinase 2,p42 MAP Kinase,p42 MAPK,p42(Mitogen-Activated Protein Kinase),MAPK1 Mitogen-Activated Protein Kinase,MAPK2 Mitogen-Activated Protein Kinase,p42(Mapk),p42(Mapk) Kinase,Extracellular Signal Regulated Kinase 2,MAP Kinase, p42,MAPK1 Mitogen Activated Protein Kinase,MAPK2 Mitogen Activated Protein Kinase,Mitogen Activated Protein Kinase 1,Mitogen Activated Protein Kinase 2

Related Publications

M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
September 2023, Journal of neuropathology and experimental neurology,
M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
March 1990, The Journal of clinical investigation,
M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
July 1994, The Journal of biological chemistry,
M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
August 1995, Investigative ophthalmology & visual science,
M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
November 1997, Leukemia,
M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
November 1986, Proceedings of the National Academy of Sciences of the United States of America,
M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
April 1986, International journal of cancer,
M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
July 1994, FEMS microbiology letters,
M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
May 2008, Antioxidants & redox signaling,
M Motevalli, and P J Goldschmidt-Clermont, and D Virgil, and P O Kwiterovich
April 1988, Clinical and investigative medicine. Medecine clinique et experimentale,
Copied contents to your clipboard!